For information on CSL Behring COVID-19 updates, please click here

For pediatric* and adult patients with primary humoral immunodeficiency

Proven. Personalized. Leader.

Hizentra PI branding image
Proven icon

Proven: Efficacy & Tolerability

Review study results

Personalized icon

Personalized: Therapeutic Options

Explore individualized therapy

Leader icon

Leader: The #1 Ig Prescribed for PI4

Learn about IgIQ support

*Age 2 and older.

Hizentra is indicated for the treatment of primary immune deficiency (PI) in adults and pediatric patients 2 years and older.

Do your PI patients have challenges with their Ig therapy?

Consider Hizentra for patients with PI who have the following:

IVIg-related adverse reactions continue to occur

Venous access and port placement issues with IV treatment

Lifestyle burdens with the lack of freedom and flexibility with IV treatment

Planning and getting to the IV infusion clinic is a constant inconvenience

Important information for healthcare professionals

Below are areas you may find especially helpful when providing Hizentra to your patients.

You are now leaving the current website.

Do you want to continue?

No Yes